Physician profile
Manoj Mathur
NPI 1992730568
$4,883.38
in general payments reported to CMS, 2019-2025
35 companies · $235 in 2025
The $235 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $549 · 2020: $394 · 2021: $1,111 · 2022: $1,101 · 2023: $714 · 2024: $780 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,729.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,729.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $671.87 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Amneal Pharmaceuticals LLC | $526.86 | 2021-2024 | Unithroid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $457.23 | 2019-2025 | Jardiance, Synjardy |
| Abbvie INC. | $371.62 | 2019-2022 | |
| Novo Nordisk INC | $335.34 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $298.06 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Sanofi-Aventis U.S. LLC | $280.54 | 2019-2024 | |
| Corcept Therapeutics | $262.33 | 2019-2025 | Korlym |
| Glaxosmithkline, LLC. | $216.45 | 2020-2023 | Trelegy Ellipta |
| Esperion Therapeutics, INC. | $176.30 | 2020-2025 | Nexletol |
| Cequr Corporation | $171.40 | 2023-2025 | Cequr Simplicity |
| Abbott Laboratories | $128.59 | 2019-2024 | Freestyle Libre 3 |
| Mannkind Corporation | $98.40 | 2021-2023 | Afrezza |
| Xeris Pharmaceuticals, INC. | $86.40 | 2021-2023 | Gvoke Hypopen |
| Nestle Healthcare Nutrition INC. | $78.06 | 2021-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $76.78 | 2019-2024 | Evenity, Prolia |
| Recordati_rare_diseases_inc. | $71.21 | 2022-2024 | Signifor Lar, Isturisa |
| Janssen Pharmaceuticals, INC | $70.87 | 2019-2020 | |
| Dexcom, INC. | $54.53 | 2025 | Dexcom G6 Transmitter |
| Becton, Dickinson and Company | $52.80 | 2020-2022 | |
| Acerus Pharmaceuticals Corporation | $44.80 | 2020-2021 | |
| Lifescan, INC. | $44.75 | 2022 | |
| Pfizer INC. | $39.63 | 2022-2025 | |
| Amarin Pharma, INC. | $36.52 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $36.51 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $34.05 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $25.69 | 2024 | Crysvita |
| Genzyme Corporation | $24.06 | 2023 | |
| Eusa Pharma (US) LLC | $23.62 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.59 | 2021 | |
| Radius Health, INC. | $17.39 | 2019 | |
| Tolmar, INC. | $16.33 | 2024 | |
| Alexion Pharmaceuticals, INC. | $13.35 | 2024 | Strensiq |
| Gilead Sciences, INC. | $12.35 | 2019 | |
| Vivus LLC | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manoj Mathur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.